Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1398667

Immune-Related Adverse Events in Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis from the FDA Adverse Event Reporting System

Provisionally accepted
Yifeng Bai Yifeng Bai *Xiaomei Wang Xiaomei Wang Xiaoqin Dai Xiaoqin Dai Yifeng Bai Yifeng Bai Honglin Hu Honglin Hu
  • University of Electronic Science and Technology of China, Chengdu, Sichuan Province, China

The final, formatted version of the article will be published soon.

    Background: The discovery and development of immune checkpoint inhibitors (ICIs) have resulted in their application as a novel therapeutic strategy for patients with small-cell lung cancer (SCLC). However, a comprehensive analysis of the potential adverse effects of ICIs in patients with SCLC remains to be conducted. Methods: Adverse event (ADE) reports relating to SCLC patients, submitted to the FDA Adverse Event Reporting System (FAERS) from the first quarter of 2013 to the second quarter of 2022, were extracted for analysis. The extracted data were subsequently screened and analyzed using the reporting odds ratio (ROR) method to assess the AE reports. Results: A total of 4,522 ADE reports were obtained from patients with SCLC who had received either chemotherapy alone or a combination of ICIs with chemotherapy. The ROR analysis identified a total of 91 immune-related adverse events in SCLC patients associated with the ICIs (SCLC-irAEs). Conclusions: This study revealed that the adverse effects resulting from irAEs in SCLC patients predominantly affected the hematologic and gastrointestinal systems, with the most severe cases potentially leading to fatality.

    Keywords: SCLC, FDA adverse event reporting system (FAERS), ICIs - Immune check point inhibitors, irAEs (immune-related adverse events), Adverse (side) effects

    Received: 10 Mar 2024; Accepted: 16 Oct 2024.

    Copyright: © 2024 Bai, Wang, Dai, Bai and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Yifeng Bai, University of Electronic Science and Technology of China, Chengdu, 611731, Sichuan Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.